Dry powder antibiotic aerosol product development : inhaled therapy for tuberculosis

dc.contributor.authorHickey, Anthony J.
dc.contributor.authorMisra, Amit
dc.contributor.authorFourie, Petrus Bernardus
dc.date.accessioned2014-04-10T09:23:06Z
dc.date.available2014-12-01T00:20:07Z
dc.date.issued2013-11
dc.description.abstractInhaled therapies offer a unique approach to the treatment of tuberculosis (TB) using a relevant target organ system as a route of administration. The number of research reports on this topic has been increasing exponentially in the last decade but studies of clinical efficacy have been rare in recent times. The challenge is to take many research findings and translate them into a strategy for product development. Dry powder inhalers are the dominant drug product under consideration by those interested in the inhaled therapy for TB. A range of factors including candidate drug, formulation, device selection, drug product testing for proof of concept, and preclinical and clinical purposes all demand different considerations. The following review is intended to raise awareness of a growing body of evidence, suggesting that inhaled therapy for TB is possible and desirable. In addition, it is intended to outline key elements of the product-development activity for this particular application that has not been discussed elsewhere in the literature. Hopefully, this will encourage those with development expertise to seriously contemplate the steps required to bring such products forward.en_US
dc.description.librarianhb2014en_US
dc.description.librarianay2014
dc.description.sponsorshipNational Institute of Allergy and Infectious Disease. Open Source Drug Discovery and CSIR-BSC0112en_US
dc.description.urihttp://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1520-6017en_US
dc.identifier.citationHickey, AJ, Misra, A & Fourie, PB 2013, 'Dry powder antibiotic aerosol product development : inhaled therapy for tuberculosis', Journal of Pharmaceutical Sciences, vol.102, no.11, pp. 3900-3907.en_US
dc.identifier.issn0022-3549 (print)
dc.identifier.issn1520-6017 (online)
dc.identifier.other10.1002/jps.23705
dc.identifier.urihttp://hdl.handle.net/2263/39637
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.rights© 2013 Wiley Periodicals, Inc. and the American Pharmacists Association.The definite version is available at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1520-6017en_US
dc.subjectAnti-infectivesen_US
dc.subjectDrug delivery systemsen_US
dc.subjectFactorial designen_US
dc.subjectFormulationen_US
dc.subjectGlobal healthen_US
dc.subjectMultivariate analysisen_US
dc.subjectPowder technologyen_US
dc.subjectPulmonary drug deliveryen_US
dc.subjectTuberculosis (TB)en_US
dc.subject.lcshInhalers -- Researchen
dc.subject.lcshTuberculosis -- Treatmenten
dc.titleDry powder antibiotic aerosol product development : inhaled therapy for tuberculosisen_US
dc.typePostprint Articleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Hickey_Dry_2013.pdf
Size:
803.4 KB
Format:
Adobe Portable Document Format
Description:
Postprint Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: